Farber Disease

Mendelian MONDO:0009218 Pathograph 27 Lysosomal Storage Disorder Sphingolipidosis

Farber disease is an ultra-rare autosomal recessive lysosomal sphingolipid storage disorder caused by biallelic ASAH1 pathogenic variants and deficient acid ceramidase activity. Impaired lysosomal ceramide catabolism causes ceramide storage with lipid-laden macrophage granulomas, inflammatory cytokine activation, and a multisystem phenotype classically including periarticular subcutaneous nodules, painful swollen or contractured joints, and progressive hoarse voice from laryngeal involvement, with variable neurologic, respiratory, visceral, skeletal, and ocular involvement.

Ask OpenScientist

Ask a research question about Farber Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Definitions
1
Inheritance
7
Pathophys.
1
Histopath.
14
Phenotypes
27
Pathograph
1
Genes
4
Treatments
1
Differentials
1
Trials
16
References
1
Deep Research
🔗

Mappings

MONDO
MONDO:0009218 Farber lipogranulomatosis
skos:exactMatch Orphanet ORPHA:333
Orphanet ORPHA:333 lists MONDO:0009218 as an exact cross-reference for Farber disease.
📘

Definitions

1
Orphanet Farber disease definition
A subcutaneous tissue disease with a spectrum from the classical triad of painful progressively deformed joints, subcutaneous nodules, and progressive hoarseness due to laryngeal involvement to variable respiratory and neurologic involvement.
OTHER
Show evidence (2 references)
ORPHA:333 SUPPORT Other
"classical triad of painful and progressively deformed joints, subcutaneous nodules, and progressive hoarseness"
Orphanet defines the core clinical triad and spectrum.
PMID:30029679 SUPPORT Human Clinical
"Typical textbook manifestations of classical FD include the formation of subcutaneous nodules, accumulation of joint contractures, and development of a hoarse voice."
Review supports the classical Farber disease triad.
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
Farber disease is inherited in an autosomal recessive pattern.
Autosomal recessive inheritance
Show evidence (2 references)
ORPHA:333 SUPPORT Other
"Autosomal recessive"
Orphanet records autosomal recessive inheritance for Farber disease.
PMID:36830643 SUPPORT Human Clinical
"Farber disease (FD) and spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME) are ultra-rare, autosomal-recessive, acid ceramidase (ACDase) deficiency disorders caused by ASAH1 gene mutations."
Review directly supports autosomal recessive ASAH1-related disease.
⚙

Pathophysiology

7
ASAH1 acid ceramidase loss of function
Biallelic ASAH1 pathogenic variants reduce or abolish lysosomal acid ceramidase activity, the N-acylsphingosine amidohydrolase that normally hydrolyzes ceramide to sphingosine and fatty acid.
ASAH1 link
N-acylsphingosine amidohydrolase activity link ↓ DECREASED
lysosome link
Downstream
Ceramide catabolism blockade Deficient acid ceramidase directly blocks ceramide hydrolysis.
Reduced acid ceramidase activity ASAH1 loss of function is measured biochemically as reduced acid ceramidase activity.
Abnormal acid ceramidase activity The proximal enzyme defect also appears as the laboratory phenotype of decreased acid ceramidase activity.
Show evidence (2 references)
PMID:29692406 SUPPORT In Vitro
"Acid ceramidase (aCDase, ASAH1) hydrolyzes lysosomal membrane ceramide into sphingosine"
Biochemical and structural work defines the enzymatic function of ASAH1 acid ceramidase.
PMID:23707712 SUPPORT Human Clinical
"These findings indicate that any functionally active acid ceramidase is absent in patient cells"
Patient-cell molecular evidence supports loss of function in severe neonatal Farber disease.
Ceramide catabolism blockade
Deficient acid ceramidase decreases lysosomal ceramide catabolism, preventing normal conversion of ceramide to sphingosine and fatty acid.
ceramide catabolic process link ↓ DECREASED
Downstream
Lysosomal ceramide storage Blocked ceramide catabolism causes lysosomal ceramide accumulation.
Show evidence (2 references)
PMID:31835809 SUPPORT Model Organism
"AC is a lipid hydrolase and deacetylates ceramide to sphingosine and free fatty acid."
Review summarizes the acid ceramidase reaction that is blocked in Farber disease.
PMID:36830643 SUPPORT Human Clinical
"These mutations lead to reduced ACDase activity and ceramide (Cer) accumulation in many tissues."
Review links ASAH1 mutations to reduced acid ceramidase activity and tissue ceramide accumulation.
Lysosomal ceramide storage
Ceramide accumulates in lysosomes and tissues, creating the storage burden thought to drive Farber disease pathology.
sphingolipid catabolic process link ↓ DECREASED
lysosome link
Downstream
Lipid-laden macrophage granulomas Ceramide storage is associated with granulomas containing lipid-filled macrophages.
Cytokine and ceramide plasma signature Ceramide storage and storage-associated inflammation are reflected in the patient plasma cytokine and ceramide profile.
Increased ceramide species Lysosomal ceramide storage is reflected by increased disease-associated ceramide species.
Central nervous system storage injury Ceramide storage can involve CNS cell types and contribute to neurologic disease.
Respiratory system involvement Multisystem ceramide storage can involve the respiratory system.
Failure to thrive Severe multisystem storage disease can manifest as failure to thrive.
Retinal ceramide storage and macrophage activation Tissue ceramide storage extends to the retina, where acid ceramidase restoration reduces ceramide accumulation and macrophage activation in a Farber disease mouse model.
Show evidence (2 references)
PMID:31835809 SUPPORT Model Organism
"AC deficiency in FD results in an accumulation of lysosomal ceramide"
Review directly states lysosomal ceramide accumulation in Farber disease.
PMID:27915031 SUPPORT Human Clinical
"In FD, bulk ceramides accumulate due to deficient ACDase activity."
Human plasma biomarker study supports ceramide accumulation due to acid ceramidase deficiency.
Lipid-laden macrophage granulomas
Storage disease recruits and activates macrophages, producing granuloma-like lesions composed of lipid-filled macrophages and neutrophils, especially near cartilage and subcutaneous tissues.
macrophage link
inflammatory response link ↑ INCREASED
Downstream
Periarticular subcutaneous nodules Granulomatous macrophage infiltration produces subcutaneous and periarticular nodules.
Arthritis Cartilage and periarticular inflammation contributes to arthritis.
Arthralgia Cartilage and periarticular inflammation contributes to painful joints.
Flexion contracture Periarticular storage and inflammation contribute to joint contractures.
Joint swelling Periarticular inflammation contributes to swollen joints.
Hoarse voice Macrophage-filled laryngeal nodules contribute to progressive hoarseness.
Show evidence (2 references)
PMID:27915031 SUPPORT Human Clinical
"They also develop granuloma-like lesions, principally at cartilage sites, that are composed of immune cells including lipid-filled macrophages and neutrophils."
Human and mouse biomarker study supports macrophage-rich granuloma-like lesions.
PMID:31835809 SUPPORT Model Organism
"Histologically, granulomas with lipid-laden macrophages are a characteristic feature of FD"
Review identifies lipid-laden macrophage granulomas as characteristic histopathology.
Cytokine and ceramide plasma signature
Farber disease plasma shows a distinct inflammatory cytokine and ceramide profile, including elevated MCP-1, IP-10, IL-6, and specific ceramide species, which may help differentiate Farber disease from juvenile idiopathic arthritis.
inflammatory response link ↑ INCREASED
Downstream
Arthritis Inflammatory mediator activation contributes to rheumatologic presentation and JIA-like misdiagnosis.
Joint swelling Inflammatory mediator activation contributes to swollen inflammatory joints.
Show evidence (2 references)
PMID:27915031 SUPPORT Human Clinical
"MCP-1, IP-10, and IL-6 were all dramatically elevated in samples from Farber patients"
Patient plasma profiling supports the inflammatory cytokine signature.
PMID:27915031 SUPPORT Human Clinical
"The cytokines identified can also be useful for the differential diagnosis of FD and JIA."
Study authors support diagnostic relevance of the cytokine signature.
Central nervous system storage injury
In severe acid ceramidase deficiency models, storage compounds accumulate in CNS neurons, endothelial cells, choroid plexus cells, and especially microglia or macrophages, producing motor and neurodegenerative findings that help explain neurologic involvement in Farber disease.
microglial cell link macrophage link
brain link
Downstream
Global developmental delay CNS involvement contributes to developmental delay in affected children.
Intellectual disability CNS involvement contributes to cognitive impairment.
CNS foam cells CNS storage includes foam-cell and microglial/macrophage pathology.
Floppy infant Early neurologic involvement contributes to infantile hypotonia.
Show evidence (2 references)
PMID:28342444 SUPPORT Model Organism
"Storage compound distribution was analyzed by mass spectrometry imaging and morphologic analyses and revealed involvement of a wide range of central nervous system cell types"
Mouse model study supports cellular CNS storage distribution.
PMID:28342444 SUPPORT Model Organism
"Neurodegeneration was also evident in specific cerebral areas in late disease."
Mouse model provides mechanistic support for CNS storage injury and neurologic decline.
Retinal ceramide storage and macrophage activation
Farber disease models show retinal ceramide accumulation and macrophage activation; ASAH1 over-expression can reduce central retinal thickening and macrophage activation in mice, supporting a storage-driven retinal mechanism.
macrophage link
retina link
Downstream
Cherry red spot of the macula Retinal storage disease is consistent with macular cherry-red spot annotation.
Show evidence (1 reference)
PMID:35902747 SUPPORT Model Organism
"reduces central retinal thickening, ceramide accumulation, macrophage activation"
Mouse retinal gene-therapy study supports ceramide and macrophage contributions to retinopathy.
✶

Histopathology

1
Granulomas with lipid-laden macrophages FREQUENT
Characteristic microscopic pathology includes granulomas composed of lipid-laden macrophages, matching the subcutaneous and periarticular nodular storage phenotype.
Show evidence (2 references)
PMID:31835809 SUPPORT Model Organism
"Histologically, granulomas with lipid-laden macrophages are a characteristic feature of FD"
Review directly supports the characteristic histopathologic finding.
PMID:27915031 SUPPORT Human Clinical
"Subcutaneous nodules, common to all reported FD patients, are composed of lipid-filled macrophages"
Patient-focused biomarker study supports the macrophage-rich histology of nodules.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Farber Disease Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

14
Cardiovascular 1
Cherry red spot of the macula FREQUENT Cherry red spot of the macula (HP:0010729)
Show evidence (1 reference)
ORPHA:333 SUPPORT Other
"HP:0010729 | Cherry red spot of the macula | Frequent (79-30%)"
Orphanet records cherry red spot of the macula as frequent.
Metabolism 1
Joint swelling VERY_FREQUENT Joint swelling (HP:0001386)
Show evidence (2 references)
ORPHA:333 SUPPORT Other
"HP:0001386 | Joint swelling | Very frequent (99-80%)"
Orphanet records joint swelling as very frequent.
PMID:36830643 SUPPORT Human Clinical
"Classic signs of FD include, but are not limited to, a hoarse voice, distended joints"
Review supports distended or swollen joints as a classic sign.
Musculoskeletal 3
Arthritis VERY_FREQUENT Arthritis (HP:0001369)
Show evidence (1 reference)
ORPHA:333 SUPPORT Other
"HP:0001369 | Arthritis | Very frequent (99-80%)"
Orphanet records arthritis as very frequent.
Flexion contracture VERY_FREQUENT Flexion contracture (HP:0001371)
Show evidence (2 references)
ORPHA:333 SUPPORT Other
"HP:0001371 | Flexion contracture | Very frequent (99-80%)"
Orphanet records flexion contracture as very frequent.
PMID:30029679 SUPPORT Human Clinical
"accumulation of joint contractures"
Review supports joint contractures in classical Farber disease.
Floppy infant FREQUENT Floppy infant (HP:0008947)
Show evidence (1 reference)
ORPHA:333 SUPPORT Other
"HP:0008947 | Floppy infant | Frequent (79-30%)"
Orphanet records floppy infant as frequent.
Nervous System 2
Global developmental delay FREQUENT Global developmental delay (HP:0001263)
Show evidence (1 reference)
ORPHA:333 SUPPORT Other
"HP:0001263 | Global developmental delay | Frequent (79-30%)"
Orphanet records global developmental delay as frequent.
Intellectual disability FREQUENT Intellectual disability (HP:0001249)
Show evidence (1 reference)
ORPHA:333 SUPPORT Other
"HP:0001249 | Intellectual disability | Frequent (79-30%)"
Orphanet records intellectual disability as frequent.
Voice 1
Hoarse voice VERY_FREQUENT Hoarse voice (HP:0001609)
Show evidence (2 references)
ORPHA:333 SUPPORT Other
"HP:0001609 | Hoarse voice | Very frequent (99-80%)"
Orphanet records hoarse voice as very frequent.
PMID:30029679 SUPPORT Human Clinical
"development of a hoarse voice"
Review supports hoarse voice as a classic Farber disease manifestation.
Constitutional 1
Arthralgia FREQUENT Arthralgia (HP:0002829)
Show evidence (1 reference)
ORPHA:333 SUPPORT Other
"HP:0002829 | Arthralgia | Frequent (79-30%)"
Orphanet records arthralgia as frequent.
Growth 1
Failure to thrive FREQUENT Failure to thrive (HP:0001508)
Show evidence (1 reference)
ORPHA:333 SUPPORT Other
"HP:0001508 | Failure to thrive | Frequent (79-30%)"
Orphanet records failure to thrive as frequent.
Other 4
Periarticular subcutaneous nodules VERY_FREQUENT Periarticular subcutaneous nodules (HP:0007470)
Show evidence (2 references)
ORPHA:333 SUPPORT Other
"HP:0007470 | Periarticular subcutaneous nodules | Very frequent (99-80%)"
Orphanet records periarticular subcutaneous nodules as very frequent.
PMID:27915031 SUPPORT Human Clinical
"Subcutaneous nodules, common to all reported FD patients, are composed of lipid-filled macrophages"
Human biomarker study supports the nodular phenotype and its macrophage composition.
Respiratory system involvement FREQUENT Abnormality of the respiratory system (HP:0002086)
Show evidence (1 reference)
ORPHA:333 SUPPORT Other
"HP:0002086 | Abnormality of the respiratory system | Frequent (79-30%)"
Orphanet records respiratory system abnormality as frequent.
CNS foam cells FREQUENT CNS foam cells (HP:0003640)
Show evidence (2 references)
ORPHA:333 SUPPORT Other
"HP:0003640 | Foam cells in visceral organs and CNS | Frequent (79-30%)"
Orphanet records foam cells in visceral organs and CNS as frequent.
PMID:28342444 SUPPORT Model Organism
"storage-laden CD68+ microglia and/or macrophages were seen as early as 3 weeks of age"
Mouse model supports CNS storage-laden macrophage or microglial pathology.
Abnormal acid ceramidase activity VERY_FREQUENT Decreased acid ceramidase activity (HP:0034053)
Show evidence (2 references)
ORPHA:333 SUPPORT Other
"HP:0012379 | Abnormal enzyme/coenzyme activity | Very frequent (99-80%)"
Orphanet records very frequent abnormal enzyme/coenzyme activity; the disease-specific abnormality is decreased acid ceramidase activity.
PMID:23707712 SUPPORT Human Clinical
"any functionally active acid ceramidase is absent in patient cells"
Patient-cell molecular evidence supports decreased or absent acid ceramidase activity.
🧬

Genetic Associations

1
Biallelic ASAH1 pathogenic variants (Causative)
Autosomal recessive inheritance
Show evidence (3 references)
ORPHA:333 SUPPORT Other
"ASAH1 | N-acylsphingosine amidohydrolase 1 | hgnc:735 | Disease-causing germline mutation(s) in"
Orphanet records ASAH1 as the disease-causing germline gene.
PMID:23707712 SUPPORT Human Clinical
"Farber disease, also known as Farber's lipogranulomatosis, is a clinically heterogeneous autosomal recessive disease caused by mutations in the ASAH1 gene."
Human molecular report directly supports ASAH1 pathogenic variants as causal.
PMID:32449975 SUPPORT Human Clinical
"Forty-five patients representing the known clinical spectrum of Farber disease"
Natural-history and variant cohort supports the molecularly curated ASAH1-related Farber disease spectrum.
💊

Treatments

4
Symptom-directed supportive management
There is no established cure for Farber disease. Current care is primarily symptom management, including pain, mobility, respiratory, and surgical management as needed.
Show evidence (1 reference)
PMID:30029679 SUPPORT Human Clinical
"Currently, there is no known cure for FD or for SMA-PME. The main treatment is symptom management."
Review directly supports symptom management as main care.
Hematopoietic stem cell transplantation
Action: hematopoietic stem cell transplantation MAXO:0000747
Allogeneic hematopoietic stem cell transplantation can improve non-neurologic manifestations, including subcutaneous nodules, joint mobility, acid ceramidase leukocyte activity, and inflammatory cytokine abnormalities, but it carries serious risks and is unsuitable for severe pulmonary or neurologic disease.
Mechanism Target:
MODULATES Lipid-laden macrophage granulomas — HSCT can reduce macrophage-filled subcutaneous and laryngeal nodules.
Show evidence (1 reference)
PMID:28275553 SUPPORT Human Clinical
"resolution of the macrophage-filled subcutaneous and laryngeal nodules in Farber disease patients after HSCT"
ERT proof-of-concept paper cites clinical HSCT-associated nodule resolution.
MODULATES Cytokine and ceramide plasma signature — HSCT-treated patient plasma showed normalized MCP-1, IP-10, and IL-6.
Show evidence (1 reference)
PMID:27915031 SUPPORT Human Clinical
"levels of these cytokines were normalized in Farber patients that had received HSCT"
Patient plasma study supports HSCT effect on inflammatory cytokines.
Show evidence (2 references)
PMID:23881344 SUPPORT Human Clinical
"to produce dramatic improvements in subcutaneous nodules and joint mobility"
Case report supports HSCT improvement in nodules and joint mobility.
PMID:27915031 SUPPORT Human Clinical
"Hematopoietic stem cell transplantation (HSCT) is currently the only treatment available for FD"
Biomarker study identifies HSCT as the available disease-modifying treatment at publication.
Recombinant acid ceramidase enzyme replacement therapy
Action: Pharmacotherapy NCIT:C15986
Recombinant human acid ceramidase enzyme replacement is an investigational disease-modifying strategy supported by Farber cell and mouse proof-of- concept studies, with clinical natural-history data collected to support potential future RVT-801 trials.
Mechanism Target:
RESTORES ASAH1 acid ceramidase loss of function — Recombinant acid ceramidase supplies the missing lysosomal enzyme activity.
Show evidence (1 reference)
PMID:28275553 SUPPORT Model Organism
"Acute dosing of rhAC in Farber mice confirmed the enzyme's bioactivity in vivo"
Mouse proof-of-concept study supports rhAC bioactivity in vivo.
RESTORES Lysosomal ceramide storage — Recombinant acid ceramidase reduced tissue ceramide storage in mice.
Show evidence (1 reference)
PMID:28275553 SUPPORT Model Organism
"repeat administration of rhAC led to significant reductions of these lipids in most tissues"
Mouse study supports correction of storage lipids after rhAC treatment.
Show evidence (2 references)
PMID:28275553 SUPPORT Model Organism
"Overall, we conclude that ERT should be further developed for this debilitating and life-threatening disorder."
Mouse and cell proof-of-concept study supports further ERT development.
clinicaltrials:NCT03233841 SUPPORT Human Clinical
"Assessing the efficacy of HSCT and the efficacy of potential future therapies (for example with RVT-801, recombinant human acid ceramidase) in Farber disease"
ClinicalTrials.gov natural-history study documents planned use of cohort data to assess future RVT-801 recombinant acid ceramidase therapy.
AAV-mediated ASAH1 gene therapy for retinopathy
Action: Pharmacotherapy NCIT:C15986
AAV-mediated ASAH1 over-expression is a preclinical ocular gene-therapy strategy that reduced retinal ceramide accumulation and macrophage activation in a Farber mouse model; it remains experimental.
Mechanism Target:
MODULATES Retinal ceramide storage and macrophage activation — AAV-mediated ASAH1 over-expression reduced retinal storage and macrophage activation in mice.
Show evidence (1 reference)
PMID:35902747 SUPPORT Model Organism
"rAAV-mediated over-expression of biologically active ACDase protein is able to rescue the anatomical retinal phenotype"
Mouse ocular gene-therapy study supports the retinal treatment mechanism.
Show evidence (1 reference)
PMID:35902747 SUPPORT Model Organism
"This study represents the first evidence of a gene therapy for Farber disease-related retinopathy."
Mouse model study supports the experimental gene-therapy approach for retinopathy.
🔬

Biochemical Markers

2
Reduced acid ceramidase activity (DECREASED)
Context: Deficient acid ceramidase activity in leukocytes or skin fibroblasts is a primary diagnostic biochemical abnormality.
Pathograph Readouts
Readout Of ASAH1 acid ceramidase loss of function Negative Diagnostic
Reduced leukocyte or fibroblast acid ceramidase activity directly reports ASAH1 acid ceramidase loss of function.
Show evidence (1 reference)
PMID:27915031 SUPPORT Human Clinical
"ACDase activity is determined in leukocytes collected from peripheral blood or from skin fibroblasts obtained by a biopsy."
Human diagnostic methods support acid ceramidase activity as a direct readout of the enzyme defect.
Show evidence (2 references)
PMID:27915031 SUPPORT Human Clinical
"Definite diagnosis of FD patients can be established by measuring ACDase enzymatic activity and/or sequencing the ASAH1 gene."
Human biomarker study supports acid ceramidase activity testing.
PMID:23707712 SUPPORT Human Clinical
"any functionally active acid ceramidase is absent in patient cells"
Neonatal case report supports severe acid ceramidase activity loss.
Increased ceramide species (INCREASED)
Context: Farber disease shows ceramide storage in tissues and altered plasma ceramide species, including specific ceramide species elevated compared with controls.
Pathograph Readouts
Readout Of Lysosomal ceramide storage Positive Diagnostic
Increased plasma or tissue ceramide species report the ceramide-storage branch caused by acid ceramidase deficiency.
Show evidence (1 reference)
PMID:27915031 SUPPORT Human Clinical
"in Farber patient plasmas only alpha-hydroxy-C18-Cer, dhC12-Cer, dhC24:1-Cer, and C22:1-Cer-1-phosphate (C22:1-Cer-1P) were significantly elevated compared to controls"
Patient plasma lipidomics supports elevated ceramide species as a readout of Farber disease ceramide storage.
Show evidence (2 references)
PMID:27915031 SUPPORT Human Clinical
"in Farber patient plasmas only alpha-hydroxy-C18-Cer, dhC12-Cer, dhC24:1-Cer, and C22:1-Cer-1-phosphate (C22:1-Cer-1P) were significantly elevated compared to controls"
Human plasma lipidomics supports specific elevated ceramide species.
PMID:28275553 SUPPORT Model Organism
"As in patients, they accumulate ceramides in most tissues and exhibit macrophage infiltration."
Mouse model summary supports tissue ceramide accumulation.
🔀

Differential Diagnoses

1

Conditions with similar clinical presentations that must be differentiated from Farber Disease:

Juvenile idiopathic arthritis
Overlapping Features Farber disease can resemble and be misdiagnosed as juvenile idiopathic arthritis because of painful joint abnormalities, contractures, and inflammation; ASAH1 sequencing, acid ceramidase activity, and plasma cytokine/ceramide biomarkers help distinguish Farber disease.
Show evidence (1 reference)
PMID:27915031 SUPPORT Human Clinical
"36% of case reports of patients with moderate FD were initially misdiagnosed as JIA"
Human biomarker study supports juvenile idiopathic arthritis as a frequent misdiagnosis.
🔬

Clinical Trials

1
NCT03233841 NOT_APPLICABLE COMPLETED
Observational and cross-sectional natural-history cohort study collecting retrospective and prospective Farber disease data, including patients with and without hematopoietic stem cell transplantation, to characterize disease activity, phenotypes, biomarkers, and future trial readiness.
Show evidence (2 references)
clinicaltrials:NCT03233841 SUPPORT Human Clinical
"The primary objective of this study is to establish the natural history of Farber disease"
ClinicalTrials.gov record establishes the Farber natural-history study objective.
clinicaltrials:NCT03233841 SUPPORT Human Clinical
"All patients diagnosed with Farber disease are eligible, including both those who have and have not undergone hematopoietic stem cell transplantation"
ClinicalTrials.gov record confirms broad patient eligibility and HSCT stratification.
{ }

Source YAML

click to show 
name: Farber Disease
category: Mendelian
creation_date: "2026-05-05T11:17:39Z"
updated_date: "2026-05-21T22:43:22Z"
synonyms:
- Acid ceramidase deficiency
- Farber lipogranulomatosis
description: >
  Farber disease is an ultra-rare autosomal recessive lysosomal sphingolipid
  storage disorder caused by biallelic ASAH1 pathogenic variants and deficient
  acid ceramidase activity. Impaired lysosomal ceramide catabolism causes
  ceramide storage with lipid-laden macrophage granulomas, inflammatory cytokine
  activation, and a multisystem phenotype classically including periarticular
  subcutaneous nodules, painful swollen or contractured joints, and progressive
  hoarse voice from laryngeal involvement, with variable neurologic,
  respiratory, visceral, skeletal, and ocular involvement.
disease_term:
  preferred_term: Farber lipogranulomatosis
  term:
    id: MONDO:0009218
    label: Farber lipogranulomatosis
parents:
- Lysosomal Storage Disorder
- Sphingolipidosis
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0009218
      label: Farber lipogranulomatosis
    mapping_predicate: skos:exactMatch
    mapping_source: Orphanet ORPHA:333
    mapping_justification: >
      Orphanet ORPHA:333 lists MONDO:0009218 as an exact cross-reference for
      Farber disease.
external_assertions:
- name: Orphanet Farber disease record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:333
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=333
  description: >
    Orphanet's ORPHA:333 structured record for Farber disease includes exact
    MONDO and OMIM cross-references, synonyms, definition, autosomal recessive
    inheritance, ASAH1 disease-gene assertion, prevalence, onset bands, and HPO
    phenotype annotations used in this entry.
  evidence:
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0009218 | Exact"
    explanation: Orphanet maps ORPHA:333 to the same MONDO identifier used by this entry.
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:228000 | Exact"
    explanation: Orphanet lists OMIM:228000 as an exact external cross-reference.
definitions:
- name: Orphanet Farber disease definition
  definition_type: OTHER
  description: >
    A subcutaneous tissue disease with a spectrum from the classical triad of
    painful progressively deformed joints, subcutaneous nodules, and progressive
    hoarseness due to laryngeal involvement to variable respiratory and
    neurologic involvement.
  evidence:
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "classical triad of painful and progressively deformed joints, subcutaneous nodules, and progressive hoarseness"
    explanation: Orphanet defines the core clinical triad and spectrum.
  - reference: PMID:30029679
    reference_title: "Acid ceramidase deficiency: Farber disease and SMA-PME."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Typical textbook manifestations of classical FD include the formation of subcutaneous nodules, accumulation of joint contractures, and development of a hoarse voice."
    explanation: Review supports the classical Farber disease triad.
inheritance:
- name: Autosomal recessive inheritance
  description: Farber disease is inherited in an autosomal recessive pattern.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Orphanet records autosomal recessive inheritance for Farber disease.
  - reference: PMID:36830643
    reference_title: "Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Farber disease (FD) and spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME) are ultra-rare, autosomal-recessive, acid ceramidase (ACDase) deficiency disorders caused by ASAH1 gene mutations."
    explanation: Review directly supports autosomal recessive ASAH1-related disease.
prevalence:
- population: Worldwide
  percentage: Unknown
  notes: >
    Orphanet records Farber disease as ultra-rare with worldwide point
    prevalence below 1 per 1,000,000.
  evidence:
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "<1 / 1 000 000 | Worldwide | Point prevalence | PMID:29048419"
    explanation: Orphanet records a worldwide point-prevalence band below 1 per 1,000,000.
  - reference: PMID:29048419
    reference_title: "A cross-sectional quantitative analysis of the natural history of Farber disease: an ultra-orphan condition with rheumatologic and neurological cardinal disease features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PurposeFarber disease (OMIM 22800) is an ultrarare progressive multisystemic"
    explanation: Natural-history study supports the ultra-rare multisystem framing.
progression:
- phase: Early-onset progressive multisystem disease
  age_range: Antenatal to childhood, most often infancy
  notes: >
    Onset can be antenatal, neonatal, infantile, or childhood. Classical disease
    begins in infancy with progressive joint, subcutaneous, laryngeal, and
    systemic involvement; severe forms may lead to death in infancy, whereas
    attenuated forms may be diagnosed later.
  evidence:
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Infancy"
    explanation: Orphanet records infancy among Farber disease onset bands.
  - reference: PMID:29048419
    reference_title: "A cross-sectional quantitative analysis of the natural history of Farber disease: an ultra-orphan condition with rheumatologic and neurological cardinal disease features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Farber disease onset is in infancy."
    explanation: Natural-history analysis supports infancy as typical onset.
  - reference: PMID:30029679
    reference_title: "Acid ceramidase deficiency: Farber disease and SMA-PME."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients may develop severe pathologies leading to death in infancy or may develop attenuated forms"
    explanation: Review supports the broad severity continuum.
genetic:
- name: Biallelic ASAH1 pathogenic variants
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  gene_term:
    preferred_term: ASAH1
    term:
      id: hgnc:735
      label: ASAH1
  notes: >
    ASAH1 encodes lysosomal acid ceramidase. Biallelic pathogenic variants cause
    acid ceramidase deficiency with Farber disease; severe neonatal cases can
    have absent functionally active acid ceramidase in patient cells.
  inheritance:
  - name: Autosomal recessive inheritance
  evidence:
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ASAH1 | N-acylsphingosine amidohydrolase 1 | hgnc:735 | Disease-causing germline mutation(s) in"
    explanation: Orphanet records ASAH1 as the disease-causing germline gene.
  - reference: PMID:23707712
    reference_title: "Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Farber disease, also known as Farber's lipogranulomatosis, is a clinically heterogeneous autosomal recessive disease caused by mutations in the ASAH1 gene."
    explanation: Human molecular report directly supports ASAH1 pathogenic variants as causal.
  - reference: PMID:32449975
    reference_title: "ASAH1 pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Forty-five patients representing the known clinical spectrum of Farber disease"
    explanation: Natural-history and variant cohort supports the molecularly curated ASAH1-related Farber disease spectrum.
pathophysiology:
- name: ASAH1 acid ceramidase loss of function
  description: >
    Biallelic ASAH1 pathogenic variants reduce or abolish lysosomal acid
    ceramidase activity, the N-acylsphingosine amidohydrolase that normally
    hydrolyzes ceramide to sphingosine and fatty acid.
  genes:
  - preferred_term: ASAH1
    term:
      id: hgnc:735
      label: ASAH1
  molecular_functions:
  - preferred_term: N-acylsphingosine amidohydrolase activity
    modifier: DECREASED
    term:
      id: GO:0017040
      label: N-acylsphingosine amidohydrolase activity
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  evidence:
  - reference: PMID:29692406
    reference_title: Structural basis for the activation of acid ceramidase.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Acid ceramidase (aCDase, ASAH1) hydrolyzes lysosomal membrane ceramide into sphingosine"
    explanation: Biochemical and structural work defines the enzymatic function of ASAH1 acid ceramidase.
  - reference: PMID:23707712
    reference_title: "Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings indicate that any functionally active acid ceramidase is absent in patient cells"
    explanation: Patient-cell molecular evidence supports loss of function in severe neonatal Farber disease.
  downstream:
  - target: Ceramide catabolism blockade
    description: Deficient acid ceramidase directly blocks ceramide hydrolysis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29692406
      reference_title: Structural basis for the activation of acid ceramidase.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Acid ceramidase (aCDase, ASAH1) hydrolyzes lysosomal membrane ceramide into sphingosine"
      explanation: Structural and biochemical work defines the reaction blocked by ASAH1 acid ceramidase loss of function.
  - target: Reduced acid ceramidase activity
    description: ASAH1 loss of function is measured biochemically as reduced acid ceramidase activity.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:27915031
      reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Definite diagnosis of FD patients can be established by measuring ACDase enzymatic activity and/or sequencing the ASAH1 gene."
      explanation: Human diagnostic evidence supports acid ceramidase activity as a direct biochemical readout of ASAH1 deficiency.
  - target: Abnormal acid ceramidase activity
    description: The proximal enzyme defect also appears as the laboratory phenotype of decreased acid ceramidase activity.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:23707712
      reference_title: "Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "any functionally active acid ceramidase is absent in patient cells"
      explanation: Patient-cell evidence supports the decreased acid ceramidase activity phenotype.
- name: Ceramide catabolism blockade
  description: >
    Deficient acid ceramidase decreases lysosomal ceramide catabolism, preventing
    normal conversion of ceramide to sphingosine and fatty acid.
  biological_processes:
  - preferred_term: ceramide catabolic process
    modifier: DECREASED
    term:
      id: GO:0046514
      label: ceramide catabolic process
  chemical_entities:
  - preferred_term: ceramide
    modifier: INCREASED
    term:
      id: CHEBI:17761
      label: ceramide
  evidence:
  - reference: PMID:31835809
    reference_title: Acid Sphingomyelinase Deficiency Ameliorates Farber Disease.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "AC is a lipid hydrolase and deacetylates ceramide to sphingosine and free fatty acid."
    explanation: Review summarizes the acid ceramidase reaction that is blocked in Farber disease.
  - reference: PMID:36830643
    reference_title: "Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These mutations lead to reduced ACDase activity and ceramide (Cer) accumulation in many tissues."
    explanation: Review links ASAH1 mutations to reduced acid ceramidase activity and tissue ceramide accumulation.
  downstream:
  - target: Lysosomal ceramide storage
    description: Blocked ceramide catabolism causes lysosomal ceramide accumulation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36830643
      reference_title: "Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These mutations lead to reduced ACDase activity and ceramide (Cer) accumulation in many tissues."
      explanation: Review evidence links reduced acid ceramidase activity to tissue ceramide accumulation.
- name: Lysosomal ceramide storage
  description: >
    Ceramide accumulates in lysosomes and tissues, creating the storage burden
    thought to drive Farber disease pathology.
  biological_processes:
  - preferred_term: sphingolipid catabolic process
    modifier: DECREASED
    term:
      id: GO:0030149
      label: sphingolipid catabolic process
  chemical_entities:
  - preferred_term: ceramide
    modifier: INCREASED
    term:
      id: CHEBI:17761
      label: ceramide
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  evidence:
  - reference: PMID:31835809
    reference_title: Acid Sphingomyelinase Deficiency Ameliorates Farber Disease.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "AC deficiency in FD results in an accumulation of lysosomal ceramide"
    explanation: Review directly states lysosomal ceramide accumulation in Farber disease.
  - reference: PMID:27915031
    reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In FD, bulk ceramides accumulate due to deficient ACDase activity."
    explanation: Human plasma biomarker study supports ceramide accumulation due to acid ceramidase deficiency.
  downstream:
  - target: Lipid-laden macrophage granulomas
    description: Ceramide storage is associated with granulomas containing lipid-filled macrophages.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:27915031
      reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "They also develop granuloma-like lesions, principally at cartilage sites, that are composed of immune cells including lipid-filled macrophages and neutrophils."
      explanation: Human and mouse Farber disease evidence connects storage disease to macrophage-rich granuloma-like lesions.
  - target: Cytokine and ceramide plasma signature
    description: >
      Ceramide storage and storage-associated inflammation are reflected in the
      patient plasma cytokine and ceramide profile.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - >
      Storage-associated macrophage infiltration and abnormal hematopoietic
      activation elevate inflammatory mediators.
    - >
      Disease-associated ceramide species accumulate systemically and are
      detectable in plasma.
    evidence:
    - reference: PMID:27915031
      reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >
        MCP-1, IP-10, and IL-6 were all dramatically elevated in samples from
        Farber patients compared to those obtained from control and JIA
        patients.
      explanation: >
        Patient plasma profiling links Farber disease to elevated inflammatory
        cytokines, supporting a downstream inflammatory biomarker branch.
    - reference: PMID:27915031
      reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >
        A unique cytokine and ceramide profile was seen in the plasma of
        Farber patients that was not observed in plasma from HSCT-treated
        Farber patients, JIA patients, or Gaucher patients.
      explanation: >
        The same human plasma study identifies the combined cytokine and
        ceramide signature as a disease-associated readout.
  - target: Increased ceramide species
    description: Lysosomal ceramide storage is reflected by increased disease-associated ceramide species.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:27915031
      reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "a-OH-C18-Cer, dhC12-Cer, dhC24:1-Cer, and C22:1-Cer-1P accumulated in plasma from patients with FD."
      explanation: Patient plasma lipidomics supports increased ceramide species as a biochemical manifestation of ceramide storage.
  - target: Central nervous system storage injury
    description: Ceramide storage can involve CNS cell types and contribute to neurologic disease.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28342444
      reference_title: Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Storage compound distribution was analyzed by mass spectrometry imaging and morphologic analyses and revealed involvement of a wide range of central nervous system cell types"
      explanation: Mouse model evidence supports CNS storage as a downstream consequence of acid ceramidase deficiency.
  - target: Respiratory system involvement
    description: Multisystem ceramide storage can involve the respiratory system.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:333
      reference_title: "Farber disease (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "respiratory and neurologic involvement"
      explanation: Orphanet places respiratory involvement within the Farber disease clinical spectrum.
  - target: Failure to thrive
    description: Severe multisystem storage disease can manifest as failure to thrive.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:333
      reference_title: "Farber disease (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001508 | Failure to thrive | Frequent (79-30%)"
      explanation: Orphanet records failure to thrive as a frequent Farber disease phenotype.
  - target: Retinal ceramide storage and macrophage activation
    description: >
      Tissue ceramide storage extends to the retina, where acid ceramidase
      restoration reduces ceramide accumulation and macrophage activation in a
      Farber disease mouse model.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:35902747
      reference_title: rAAV-mediated over-expression of acid ceramidase prevents retinopathy in a mouse model of Farber lipogranulomatosis.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >
        ASAH1 over-expression significantly reduces central retinal thickening,
        ceramide accumulation, macrophage activation and limits fundus
        hyper-reflectivity and auto-fluorescence in FD mice
      explanation: >
        In the Farber mouse retina, restoring ASAH1 reduces ceramide accumulation
        and macrophage activation, supporting retinal storage pathology as a
        tissue-specific branch of the ceramide storage mechanism.
- name: Lipid-laden macrophage granulomas
  description: >
    Storage disease recruits and activates macrophages, producing granuloma-like
    lesions composed of lipid-filled macrophages and neutrophils, especially near
    cartilage and subcutaneous tissues.
  cell_types:
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:27915031
    reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "They also develop granuloma-like lesions, principally at cartilage sites, that are composed of immune cells including lipid-filled macrophages and neutrophils."
    explanation: Human and mouse biomarker study supports macrophage-rich granuloma-like lesions.
  - reference: PMID:31835809
    reference_title: Acid Sphingomyelinase Deficiency Ameliorates Farber Disease.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Histologically, granulomas with lipid-laden macrophages are a characteristic feature of FD"
    explanation: Review identifies lipid-laden macrophage granulomas as characteristic histopathology.
  downstream:
  - target: Periarticular subcutaneous nodules
    description: Granulomatous macrophage infiltration produces subcutaneous and periarticular nodules.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:27915031
      reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Subcutaneous nodules, common to all reported FD patients, are composed of lipid-filled macrophages"
      explanation: Patient nodule histology supports lipid-filled macrophage granulomas as the source of subcutaneous nodules.
  - target: Arthritis
    description: Cartilage and periarticular inflammation contributes to arthritis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:333
      reference_title: "Farber disease (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001369 | Arthritis | Very frequent (99-80%)"
      explanation: Orphanet records arthritis as a very frequent Farber disease phenotype.
  - target: Arthralgia
    description: Cartilage and periarticular inflammation contributes to painful joints.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27915031
      reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Joint abnormalities (e.g., contractures, pain) may also occur in Juvenile Idiopathic Arthritis (JIA), resulting in the misdiagnosis of Farber patients"
      explanation: Human Farber disease discussion supports joint pain as part of the inflammatory joint presentation.
  - target: Flexion contracture
    description: Periarticular storage and inflammation contribute to joint contractures.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30029679
      reference_title: "Acid ceramidase deficiency: Farber disease and SMA-PME."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "accumulation of joint contractures"
      explanation: Review of human Farber disease supports joint contractures in the classical phenotype.
  - target: Joint swelling
    description: Periarticular inflammation contributes to swollen joints.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:36830643
      reference_title: "Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Classic signs of FD include, but are not limited to, a hoarse voice, distended joints"
      explanation: Review evidence supports distended joints as a classic Farber disease sign.
  - target: Hoarse voice
    description: Macrophage-filled laryngeal nodules contribute to progressive hoarseness.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28275553
      reference_title: "Enzyme replacement therapy for Farber disease: Proof-of-concept studies in cells and mice."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "resolution of the macrophage-filled subcutaneous and laryngeal nodules in Farber disease patients after HSCT"
      explanation: Clinical HSCT experience supports macrophage-filled laryngeal nodules as part of the Farber disease nodular phenotype.
- name: Cytokine and ceramide plasma signature
  description: >
    Farber disease plasma shows a distinct inflammatory cytokine and ceramide
    profile, including elevated MCP-1, IP-10, IL-6, and specific ceramide
    species, which may help differentiate Farber disease from juvenile
    idiopathic arthritis.
  biological_processes:
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  chemical_entities:
  - preferred_term: ceramide
    modifier: INCREASED
    term:
      id: CHEBI:17761
      label: ceramide
  evidence:
  - reference: PMID:27915031
    reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MCP-1, IP-10, and IL-6 were all dramatically elevated in samples from Farber patients"
    explanation: Patient plasma profiling supports the inflammatory cytokine signature.
  - reference: PMID:27915031
    reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The cytokines identified can also be useful for the differential diagnosis of FD and JIA."
    explanation: Study authors support diagnostic relevance of the cytokine signature.
  downstream:
  - target: Arthritis
    description: Inflammatory mediator activation contributes to rheumatologic presentation and JIA-like misdiagnosis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27915031
      reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "MIP-1a, IP-10, IL-6, and IL-12 are implicated in arthritis"
      explanation: Patient and mouse cytokine profiling supports inflammatory mediators as contributors to the arthritis-like presentation.
  - target: Joint swelling
    description: Inflammatory mediator activation contributes to swollen inflammatory joints.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27915031
      reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Joint abnormalities (e.g., contractures, pain) may also occur in Juvenile Idiopathic Arthritis (JIA), resulting in the misdiagnosis of Farber patients"
      explanation: Human Farber disease discussion supports inflammatory joint disease in the Farber/JIA-like presentation.
- name: Central nervous system storage injury
  description: >
    In severe acid ceramidase deficiency models, storage compounds accumulate in
    CNS neurons, endothelial cells, choroid plexus cells, and especially
    microglia or macrophages, producing motor and neurodegenerative findings
    that help explain neurologic involvement in Farber disease.
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  cell_types:
  - preferred_term: microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  chemical_entities:
  - preferred_term: ceramide
    modifier: INCREASED
    term:
      id: CHEBI:17761
      label: ceramide
  evidence:
  - reference: PMID:28342444
    reference_title: Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Storage compound distribution was analyzed by mass spectrometry imaging and morphologic analyses and revealed involvement of a wide range of central nervous system cell types"
    explanation: Mouse model study supports cellular CNS storage distribution.
  - reference: PMID:28342444
    reference_title: Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Neurodegeneration was also evident in specific cerebral areas in late disease."
    explanation: Mouse model provides mechanistic support for CNS storage injury and neurologic decline.
  downstream:
  - target: Global developmental delay
    description: CNS involvement contributes to developmental delay in affected children.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:333
      reference_title: "Farber disease (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001263 | Global developmental delay | Frequent (79-30%)"
      explanation: Orphanet records global developmental delay as a frequent Farber disease phenotype.
  - target: Intellectual disability
    description: CNS involvement contributes to cognitive impairment.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:333
      reference_title: "Farber disease (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001249 | Intellectual disability | Frequent (79-30%)"
      explanation: Orphanet records intellectual disability as a frequent Farber disease phenotype.
  - target: CNS foam cells
    description: CNS storage includes foam-cell and microglial/macrophage pathology.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28342444
      reference_title: Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "storage-laden CD68+ microglia and/or macrophages were seen as early as 3 weeks of age"
      explanation: Mouse CNS pathology directly supports storage-laden CNS microglia/macrophages.
  - target: Floppy infant
    description: Early neurologic involvement contributes to infantile hypotonia.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:333
      reference_title: "Farber disease (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0008947 | Floppy infant | Frequent (79-30%)"
      explanation: Orphanet records floppy infant as a frequent Farber disease phenotype.
- name: Retinal ceramide storage and macrophage activation
  description: >
    Farber disease models show retinal ceramide accumulation and macrophage
    activation; ASAH1 over-expression can reduce central retinal thickening and
    macrophage activation in mice, supporting a storage-driven retinal mechanism.
  locations:
  - preferred_term: retina
    term:
      id: UBERON:0000966
      label: retina
  cell_types:
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  chemical_entities:
  - preferred_term: ceramide
    modifier: INCREASED
    term:
      id: CHEBI:17761
      label: ceramide
  evidence:
  - reference: PMID:35902747
    reference_title: rAAV-mediated over-expression of acid ceramidase prevents retinopathy in a mouse model of Farber lipogranulomatosis.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "reduces central retinal thickening, ceramide accumulation, macrophage activation"
    explanation: Mouse retinal gene-therapy study supports ceramide and macrophage contributions to retinopathy.
  downstream:
  - target: Cherry red spot of the macula
    description: Retinal storage disease is consistent with macular cherry-red spot annotation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:333
      reference_title: "Farber disease (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0010729 | Cherry red spot of the macula | Frequent (79-30%)"
      explanation: Orphanet records cherry red spot of the macula as a frequent Farber disease phenotype.
phenotypes:
- name: Periarticular subcutaneous nodules
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Periarticular subcutaneous nodules
    term:
      id: HP:0007470
      label: Periarticular subcutaneous nodules
  evidence:
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007470 | Periarticular subcutaneous nodules | Very frequent (99-80%)"
    explanation: Orphanet records periarticular subcutaneous nodules as very frequent.
  - reference: PMID:27915031
    reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Subcutaneous nodules, common to all reported FD patients, are composed of lipid-filled macrophages"
    explanation: Human biomarker study supports the nodular phenotype and its macrophage composition.
- name: Arthritis
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Arthritis
    term:
      id: HP:0001369
      label: Arthritis
  evidence:
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001369 | Arthritis | Very frequent (99-80%)"
    explanation: Orphanet records arthritis as very frequent.
- name: Arthralgia
  category: Musculoskeletal
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Arthralgia
    term:
      id: HP:0002829
      label: Arthralgia
  evidence:
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002829 | Arthralgia | Frequent (79-30%)"
    explanation: Orphanet records arthralgia as frequent.
- name: Flexion contracture
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Flexion contracture
    term:
      id: HP:0001371
      label: Flexion contracture
  evidence:
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001371 | Flexion contracture | Very frequent (99-80%)"
    explanation: Orphanet records flexion contracture as very frequent.
  - reference: PMID:30029679
    reference_title: "Acid ceramidase deficiency: Farber disease and SMA-PME."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "accumulation of joint contractures"
    explanation: Review supports joint contractures in classical Farber disease.
- name: Joint swelling
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Joint swelling
    term:
      id: HP:0001386
      label: Joint swelling
  evidence:
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001386 | Joint swelling | Very frequent (99-80%)"
    explanation: Orphanet records joint swelling as very frequent.
  - reference: PMID:36830643
    reference_title: "Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Classic signs of FD include, but are not limited to, a hoarse voice, distended joints"
    explanation: Review supports distended or swollen joints as a classic sign.
- name: Hoarse voice
  category: Respiratory
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hoarse voice
    term:
      id: HP:0001609
      label: Hoarse voice
  evidence:
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001609 | Hoarse voice | Very frequent (99-80%)"
    explanation: Orphanet records hoarse voice as very frequent.
  - reference: PMID:30029679
    reference_title: "Acid ceramidase deficiency: Farber disease and SMA-PME."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "development of a hoarse voice"
    explanation: Review supports hoarse voice as a classic Farber disease manifestation.
- name: Respiratory system involvement
  category: Respiratory
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Abnormality of the respiratory system
    term:
      id: HP:0002086
      label: Abnormality of the respiratory system
  evidence:
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002086 | Abnormality of the respiratory system | Frequent (79-30%)"
    explanation: Orphanet records respiratory system abnormality as frequent.
- name: Failure to thrive
  category: Growth
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001508 | Failure to thrive | Frequent (79-30%)"
    explanation: Orphanet records failure to thrive as frequent.
- name: Floppy infant
  category: Neurologic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Floppy infant
    term:
      id: HP:0008947
      label: Floppy infant
  evidence:
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0008947 | Floppy infant | Frequent (79-30%)"
    explanation: Orphanet records floppy infant as frequent.
- name: Global developmental delay
  category: Neurologic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001263 | Global developmental delay | Frequent (79-30%)"
    explanation: Orphanet records global developmental delay as frequent.
- name: Intellectual disability
  category: Neurologic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001249 | Intellectual disability | Frequent (79-30%)"
    explanation: Orphanet records intellectual disability as frequent.
- name: CNS foam cells
  category: Histopathologic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: CNS foam cells
    term:
      id: HP:0003640
      label: CNS foam cells
  evidence:
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003640 | Foam cells in visceral organs and CNS | Frequent (79-30%)"
    explanation: Orphanet records foam cells in visceral organs and CNS as frequent.
  - reference: PMID:28342444
    reference_title: Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "storage-laden CD68+ microglia and/or macrophages were seen as early as 3 weeks of age"
    explanation: Mouse model supports CNS storage-laden macrophage or microglial pathology.
- name: Cherry red spot of the macula
  category: Ophthalmologic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Cherry red spot of the macula
    term:
      id: HP:0010729
      label: Cherry red spot of the macula
  evidence:
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0010729 | Cherry red spot of the macula | Frequent (79-30%)"
    explanation: Orphanet records cherry red spot of the macula as frequent.
- name: Abnormal acid ceramidase activity
  category: Laboratory
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Decreased acid ceramidase activity
    term:
      id: HP:0034053
      label: Decreased acid ceramidase activity
  evidence:
  - reference: ORPHA:333
    reference_title: "Farber disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0012379 | Abnormal enzyme/coenzyme activity | Very frequent (99-80%)"
    explanation: Orphanet records very frequent abnormal enzyme/coenzyme activity; the disease-specific abnormality is decreased acid ceramidase activity.
  - reference: PMID:23707712
    reference_title: "Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "any functionally active acid ceramidase is absent in patient cells"
    explanation: Patient-cell molecular evidence supports decreased or absent acid ceramidase activity.
histopathology:
- name: Granulomas with lipid-laden macrophages
  description: >
    Characteristic microscopic pathology includes granulomas composed of
    lipid-laden macrophages, matching the subcutaneous and periarticular nodular
    storage phenotype.
  frequency: FREQUENT
  evidence:
  - reference: PMID:31835809
    reference_title: Acid Sphingomyelinase Deficiency Ameliorates Farber Disease.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Histologically, granulomas with lipid-laden macrophages are a characteristic feature of FD"
    explanation: Review directly supports the characteristic histopathologic finding.
  - reference: PMID:27915031
    reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Subcutaneous nodules, common to all reported FD patients, are composed of lipid-filled macrophages"
    explanation: Patient-focused biomarker study supports the macrophage-rich histology of nodules.
biochemical:
- name: Reduced acid ceramidase activity
  presence: DECREASED
  context: >
    Deficient acid ceramidase activity in leukocytes or skin fibroblasts is a
    primary diagnostic biochemical abnormality.
  readouts:
  - target: ASAH1 acid ceramidase loss of function
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Reduced leukocyte or fibroblast acid ceramidase activity directly reports ASAH1 acid ceramidase loss of function.
    evidence:
    - reference: PMID:27915031
      reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "ACDase activity is determined in leukocytes collected from peripheral blood or from skin fibroblasts obtained by a biopsy."
      explanation: Human diagnostic methods support acid ceramidase activity as a direct readout of the enzyme defect.
  evidence:
  - reference: PMID:27915031
    reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Definite diagnosis of FD patients can be established by measuring ACDase enzymatic activity and/or sequencing the ASAH1 gene."
    explanation: Human biomarker study supports acid ceramidase activity testing.
  - reference: PMID:23707712
    reference_title: "Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "any functionally active acid ceramidase is absent in patient cells"
    explanation: Neonatal case report supports severe acid ceramidase activity loss.
- name: Increased ceramide species
  presence: INCREASED
  context: >
    Farber disease shows ceramide storage in tissues and altered plasma ceramide
    species, including specific ceramide species elevated compared with controls.
  biomarker_term:
    preferred_term: ceramide
    term:
      id: CHEBI:17761
      label: ceramide
  readouts:
  - target: Lysosomal ceramide storage
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Increased plasma or tissue ceramide species report the ceramide-storage branch caused by acid ceramidase deficiency.
    evidence:
    - reference: PMID:27915031
      reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "in Farber patient plasmas only alpha-hydroxy-C18-Cer, dhC12-Cer, dhC24:1-Cer, and C22:1-Cer-1-phosphate (C22:1-Cer-1P) were significantly elevated compared to controls"
      explanation: Patient plasma lipidomics supports elevated ceramide species as a readout of Farber disease ceramide storage.
  evidence:
  - reference: PMID:27915031
    reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "in Farber patient plasmas only alpha-hydroxy-C18-Cer, dhC12-Cer, dhC24:1-Cer, and C22:1-Cer-1-phosphate (C22:1-Cer-1P) were significantly elevated compared to controls"
    explanation: Human plasma lipidomics supports specific elevated ceramide species.
  - reference: PMID:28275553
    reference_title: "Enzyme replacement therapy for Farber disease: Proof-of-concept studies in cells and mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "As in patients, they accumulate ceramides in most tissues and exhibit macrophage infiltration."
    explanation: Mouse model summary supports tissue ceramide accumulation.
diagnosis:
- name: Acid ceramidase enzyme activity assay
  description: >
    Diagnosis can be established biochemically by measuring deficient acid
    ceramidase activity in leukocytes or skin fibroblasts.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  evidence:
  - reference: PMID:27915031
    reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ACDase activity is determined in leukocytes collected from peripheral blood or from skin fibroblasts obtained by a biopsy."
    explanation: Human biomarker study supports leukocyte or fibroblast enzyme activity testing.
  - reference: PMID:31835809
    reference_title: Acid Sphingomyelinase Deficiency Ameliorates Farber Disease.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "FD is diagnosed by demonstration of reduced AC activity and abnormally high ceramide levels"
    explanation: Review supports reduced acid ceramidase activity and elevated ceramide as diagnostic evidence.
- name: ASAH1 molecular genetic testing
  description: >
    Molecular genetic testing confirms biallelic ASAH1 pathogenic variants and
    supports family-based diagnosis and recurrence-risk assessment.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: MAXO:0000127
      label: genetic testing
  evidence:
  - reference: PMID:27915031
    reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Definite diagnosis of FD patients can be established by measuring ACDase enzymatic activity and/or sequencing the ASAH1 gene."
    explanation: Human biomarker study supports ASAH1 sequencing as diagnostic confirmation.
- name: Blood biomarker development study
  description: >
    A multicenter epidemiologic ClinicalTrials.gov protocol evaluated mass
    spectrometry-based blood biomarkers for earlier and sensitive Farber disease
    diagnosis.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  evidence:
  - reference: clinicaltrials:NCT02298634
    reference_title: "Biomarker for Farber Disease - An International, Multicenter, Epidemiological Protocol"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Farber disease from the blood"
    explanation: ClinicalTrials.gov record supports a Farber disease blood biomarker study.
treatments:
- name: Symptom-directed supportive management
  description: >
    There is no established cure for Farber disease. Current care is primarily
    symptom management, including pain, mobility, respiratory, and surgical
    management as needed.
  evidence:
  - reference: PMID:30029679
    reference_title: "Acid ceramidase deficiency: Farber disease and SMA-PME."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Currently, there is no known cure for FD or for SMA-PME. The main treatment is symptom management."
    explanation: Review directly supports symptom management as main care.
- name: Hematopoietic stem cell transplantation
  description: >
    Allogeneic hematopoietic stem cell transplantation can improve
    non-neurologic manifestations, including subcutaneous nodules, joint
    mobility, acid ceramidase leukocyte activity, and inflammatory cytokine
    abnormalities, but it carries serious risks and is unsuitable for severe
    pulmonary or neurologic disease.
  treatment_term:
    preferred_term: hematopoietic stem cell transplantation
    term:
      id: MAXO:0000747
      label: hematopoietic stem cell transplantation
  target_mechanisms:
  - target: Lipid-laden macrophage granulomas
    treatment_effect: MODULATES
    description: HSCT can reduce macrophage-filled subcutaneous and laryngeal nodules.
    evidence:
    - reference: PMID:28275553
      reference_title: "Enzyme replacement therapy for Farber disease: Proof-of-concept studies in cells and mice."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "resolution of the macrophage-filled subcutaneous and laryngeal nodules in Farber disease patients after HSCT"
      explanation: ERT proof-of-concept paper cites clinical HSCT-associated nodule resolution.
  - target: Cytokine and ceramide plasma signature
    treatment_effect: MODULATES
    description: HSCT-treated patient plasma showed normalized MCP-1, IP-10, and IL-6.
    evidence:
    - reference: PMID:27915031
      reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "levels of these cytokines were normalized in Farber patients that had received HSCT"
      explanation: Patient plasma study supports HSCT effect on inflammatory cytokines.
  evidence:
  - reference: PMID:23881344
    reference_title: "Odontoid infiltration and spinal compression in Farber Disease: reversal by haematopoietic stem cell transplantation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "to produce dramatic improvements in subcutaneous nodules and joint mobility"
    explanation: Case report supports HSCT improvement in nodules and joint mobility.
  - reference: PMID:27915031
    reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hematopoietic stem cell transplantation (HSCT) is currently the only treatment available for FD"
    explanation: Biomarker study identifies HSCT as the available disease-modifying treatment at publication.
- name: Recombinant acid ceramidase enzyme replacement therapy
  description: >
    Recombinant human acid ceramidase enzyme replacement is an investigational
    disease-modifying strategy supported by Farber cell and mouse proof-of-
    concept studies, with clinical natural-history data collected to support
    potential future RVT-801 trials.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: ASAH1 acid ceramidase loss of function
    treatment_effect: RESTORES
    description: Recombinant acid ceramidase supplies the missing lysosomal enzyme activity.
    evidence:
    - reference: PMID:28275553
      reference_title: "Enzyme replacement therapy for Farber disease: Proof-of-concept studies in cells and mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Acute dosing of rhAC in Farber mice confirmed the enzyme's bioactivity in vivo"
      explanation: Mouse proof-of-concept study supports rhAC bioactivity in vivo.
  - target: Lysosomal ceramide storage
    treatment_effect: RESTORES
    description: Recombinant acid ceramidase reduced tissue ceramide storage in mice.
    evidence:
    - reference: PMID:28275553
      reference_title: "Enzyme replacement therapy for Farber disease: Proof-of-concept studies in cells and mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "repeat administration of rhAC led to significant reductions of these lipids in most tissues"
      explanation: Mouse study supports correction of storage lipids after rhAC treatment.
  evidence:
  - reference: PMID:28275553
    reference_title: "Enzyme replacement therapy for Farber disease: Proof-of-concept studies in cells and mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Overall, we conclude that ERT should be further developed for this debilitating and life-threatening disorder."
    explanation: Mouse and cell proof-of-concept study supports further ERT development.
  - reference: clinicaltrials:NCT03233841
    reference_title: Observational and Cross-Sectional Cohort Study of the Natural History and Phenotypic Spectrum of Farber Disease
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Assessing the efficacy of HSCT and the efficacy of potential future therapies (for example with RVT-801, recombinant human acid ceramidase) in Farber disease"
    explanation: ClinicalTrials.gov natural-history study documents planned use of cohort data to assess future RVT-801 recombinant acid ceramidase therapy.
- name: AAV-mediated ASAH1 gene therapy for retinopathy
  description: >
    AAV-mediated ASAH1 over-expression is a preclinical ocular gene-therapy
    strategy that reduced retinal ceramide accumulation and macrophage activation
    in a Farber mouse model; it remains experimental.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Retinal ceramide storage and macrophage activation
    treatment_effect: MODULATES
    description: AAV-mediated ASAH1 over-expression reduced retinal storage and macrophage activation in mice.
    evidence:
    - reference: PMID:35902747
      reference_title: rAAV-mediated over-expression of acid ceramidase prevents retinopathy in a mouse model of Farber lipogranulomatosis.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "rAAV-mediated over-expression of biologically active ACDase protein is able to rescue the anatomical retinal phenotype"
      explanation: Mouse ocular gene-therapy study supports the retinal treatment mechanism.
  evidence:
  - reference: PMID:35902747
    reference_title: rAAV-mediated over-expression of acid ceramidase prevents retinopathy in a mouse model of Farber lipogranulomatosis.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "This study represents the first evidence of a gene therapy for Farber disease-related retinopathy."
    explanation: Mouse model study supports the experimental gene-therapy approach for retinopathy.
differential_diagnoses:
- name: Juvenile idiopathic arthritis
  description: >
    Farber disease can resemble and be misdiagnosed as juvenile idiopathic
    arthritis because of painful joint abnormalities, contractures, and
    inflammation; ASAH1 sequencing, acid ceramidase activity, and plasma
    cytokine/ceramide biomarkers help distinguish Farber disease.
  evidence:
  - reference: PMID:27915031
    reference_title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "36% of case reports of patients with moderate FD were initially misdiagnosed as JIA"
    explanation: Human biomarker study supports juvenile idiopathic arthritis as a frequent misdiagnosis.
clinical_trials:
- name: NCT03233841
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >
    Observational and cross-sectional natural-history cohort study collecting
    retrospective and prospective Farber disease data, including patients with
    and without hematopoietic stem cell transplantation, to characterize disease
    activity, phenotypes, biomarkers, and future trial readiness.
  evidence:
  - reference: clinicaltrials:NCT03233841
    reference_title: Observational and Cross-Sectional Cohort Study of the Natural History and Phenotypic Spectrum of Farber Disease
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The primary objective of this study is to establish the natural history of Farber disease"
    explanation: ClinicalTrials.gov record establishes the Farber natural-history study objective.
  - reference: clinicaltrials:NCT03233841
    reference_title: Observational and Cross-Sectional Cohort Study of the Natural History and Phenotypic Spectrum of Farber Disease
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients diagnosed with Farber disease are eligible, including both those who have and have not undergone hematopoietic stem cell transplantation"
    explanation: ClinicalTrials.gov record confirms broad patient eligibility and HSCT stratification.
references:
- reference: ORPHA:333
  title: "Farber disease"
  found_in:
  - Farber_Disease-deep-research-fallback.md
- reference: PMID:29595935
  title: ASAH1-Related Disorders.
  tags:
  - GeneReviews
  found_in:
  - Farber_Disease-deep-research-fallback.md
- reference: PMID:29048419
  title: "A cross-sectional quantitative analysis of the natural history of Farber disease: an ultra-orphan condition with rheumatologic and neurological cardinal disease features."
  found_in:
  - Farber_Disease-deep-research-fallback.md
- reference: PMID:30029679
  title: "Acid ceramidase deficiency: Farber disease and SMA-PME."
  found_in:
  - Farber_Disease-deep-research-fallback.md
- reference: PMID:36830643
  title: "Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions."
  found_in:
  - Farber_Disease-deep-research-fallback.md
- reference: PMID:32449975
  title: "ASAH1 pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy."
  found_in:
  - Farber_Disease-deep-research-fallback.md
- reference: PMID:23707712
  title: "Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene."
  found_in:
  - Farber_Disease-deep-research-fallback.md
- reference: PMID:29692406
  title: Structural basis for the activation of acid ceramidase.
  found_in:
  - Farber_Disease-deep-research-fallback.md
- reference: PMID:31835809
  title: Acid Sphingomyelinase Deficiency Ameliorates Farber Disease.
  found_in:
  - Farber_Disease-deep-research-fallback.md
- reference: PMID:27915031
  title: Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
  found_in:
  - Farber_Disease-deep-research-fallback.md
- reference: PMID:28342444
  title: Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities.
  found_in:
  - Farber_Disease-deep-research-fallback.md
- reference: PMID:23881344
  title: "Odontoid infiltration and spinal compression in Farber Disease: reversal by haematopoietic stem cell transplantation."
  found_in:
  - Farber_Disease-deep-research-fallback.md
- reference: PMID:28275553
  title: "Enzyme replacement therapy for Farber disease: Proof-of-concept studies in cells and mice."
  found_in:
  - Farber_Disease-deep-research-fallback.md
- reference: PMID:35902747
  title: rAAV-mediated over-expression of acid ceramidase prevents retinopathy in a mouse model of Farber lipogranulomatosis.
  found_in:
  - Farber_Disease-deep-research-fallback.md
- reference: clinicaltrials:NCT03233841
  title: Observational and Cross-Sectional Cohort Study of the Natural History and Phenotypic Spectrum of Farber Disease
- reference: clinicaltrials:NCT02298634
  title: "Biomarker for Farber Disease - An International, Multicenter, Epidemiological Protocol"
📚

References & Deep Research

References

16
ORPHA:333
Farber disease
No top-level findings curated for this source.
PMID:29595935
ASAH1-Related Disorders.
No top-level findings curated for this source.
PMID:29048419
A cross-sectional quantitative analysis of the natural history of Farber disease: an ultra-orphan condition with rheumatologic and neurological cardinal disease features.
No top-level findings curated for this source.
PMID:30029679
Acid ceramidase deficiency: Farber disease and SMA-PME.
No top-level findings curated for this source.
PMID:36830643
Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions.
No top-level findings curated for this source.
PMID:32449975
ASAH1 pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy.
No top-level findings curated for this source.
PMID:23707712
Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene.
No top-level findings curated for this source.
PMID:29692406
Structural basis for the activation of acid ceramidase.
No top-level findings curated for this source.
PMID:31835809
Acid Sphingomyelinase Deficiency Ameliorates Farber Disease.
No top-level findings curated for this source.
PMID:27915031
Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
No top-level findings curated for this source.
PMID:28342444
Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities.
No top-level findings curated for this source.
PMID:23881344
Odontoid infiltration and spinal compression in Farber Disease: reversal by haematopoietic stem cell transplantation.
No top-level findings curated for this source.
PMID:28275553
Enzyme replacement therapy for Farber disease: Proof-of-concept studies in cells and mice.
No top-level findings curated for this source.
PMID:35902747
rAAV-mediated over-expression of acid ceramidase prevents retinopathy in a mouse model of Farber lipogranulomatosis.
No top-level findings curated for this source.
clinicaltrials:NCT03233841
Observational and Cross-Sectional Cohort Study of the Natural History and Phenotypic Spectrum of Farber Disease
No top-level findings curated for this source.
clinicaltrials:NCT02298634
Biomarker for Farber Disease - An International, Multicenter, Epidemiological Protocol
No top-level findings curated for this source.

Deep Research

1
Fallback ▸
Farber Disease Deep Research Fallback

Farber Disease Deep Research Fallback

Provider Attempts

  • 2026-05-05T11:20Z: just research-disorder falcon Farber_Disease produced no artifact after an extended silent wait and was interrupted.
  • 2026-05-05T11:31Z: just research-disorder openai Farber_Disease produced no artifact after a bounded silent wait and was interrupted.

No provider-generated deep-research narrative was available within the bounded runtime. Curation therefore proceeded from generated structured Orphanet evidence and fetched PubMed/ClinicalTrials.gov caches, without hand-editing any references_cache/*.md files.

Evidence Scope Used For Curation

  • ORPHA:333 structured record for disease definition, exact MONDO/OMIM mapping, ASAH1 disease-gene association, autosomal recessive inheritance, worldwide point prevalence, onset bands, and HPO phenotype frequencies.
  • PMID:29048419 for the cross-sectional natural-history cohort framing Farber disease as an ultra-rare progressive multisystem disorder with infancy onset.
  • PMID:30029679, PMID:36830643, and PMID:32449975 for clinical-spectrum review, ASAH1 acid ceramidase deficiency, classical triad, phenotype variability, and molecularly confirmed natural-history cases.
  • PMID:23707712 and PMID:29692406 for the molecular basis of ASAH1 loss of function and acid ceramidase enzymatic function.
  • PMID:31835809 and PMID:27915031 for lysosomal ceramide accumulation, lipid-laden macrophage granulomas, inflammatory cytokine/ceramide biomarkers, and Farber disease versus juvenile idiopathic arthritis differentiation.
  • PMID:28342444 and PMID:35902747 for CNS and retinal model mechanisms.
  • PMID:23881344 and PMID:28275553 for HSCT and recombinant acid ceramidase enzyme replacement evidence.
  • ClinicalTrials.gov NCT03233841 and NCT02298634 for natural-history and blood biomarker study context.

Curation Conclusions

Farber disease is an autosomal recessive ASAH1 acid ceramidase deficiency. Reduced N-acylsphingosine amidohydrolase activity blocks lysosomal ceramide catabolism, causing ceramide storage, macrophage-rich granulomatous lesions, and inflammatory cytokine/ceramide plasma abnormalities. The clinical signature is the classic triad of periarticular/subcutaneous nodules, painful swollen or contractured joints, and hoarse voice, with variable neurologic, respiratory, visceral, skeletal, and ocular involvement. Diagnosis is supported by deficient acid ceramidase activity, ASAH1 molecular testing, ceramide/biomarker assays, and awareness of juvenile idiopathic arthritis misdiagnosis. Treatment remains largely symptom directed; HSCT can improve selected non-neurologic features but has important limitations, while recombinant acid ceramidase ERT and AAV-ASAH1 retinal gene therapy remain investigational/preclinical in the cited evidence.